# BioStem Technologies Inc. (BSEM)

Source: https://www.quantisnow.com/company/BSEM
Generated: 2026-11-18T14:15:24.754Z

- Ticker: BSEM
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- SEC CIK: 0001658678

## About

BioStem Technologies, Inc. is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain, CryoTek and SteriTek processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine.

## Latest BSEM news and filings

- 2026-11-13 21:30 UTC [SEC Form 4] [Chief Financial Officer Poe Brandon converted options into 2,699 shares, increasing direct ownership by 5% to 60,763 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-poe-brandon-converted-options-into-2699-shares-6790942)
- 2026-11-12 21:30 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by BioStem Technologies Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-biostem-technologies-inc-6788442)
- 2026-11-12 21:05 UTC [SEC Form 8-K] [BioStem Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/biostem-technologies-inc-filed-sec-form-8-k-results-of-operations-6787755)
- 2026-11-12 21:05 UTC [Earnings] [BioStem Technologies Reports Third Quarter 2026 Financial Results; Grows Hospital Revenue for Second Consecutive Quarter as Customers Expand Use of Portfolio](https://www.quantisnow.com/insight/biostem-technologies-reports-third-quarter-2026-financial-results-grows-hospital-6787626)
- 2026-11-10 21:30 UTC [SEC Form 4] [Chief Accounting Officer Fortunato Michael A converted options into 970 shares, increasing direct ownership by 1% to 69,634 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-accounting-officer-fortunato-michael-a-converted-options-into-970-6784340)
- 2026-11-10 21:15 UTC [SEC Schedule 13G] [SEC Form SCHEDULE 13G filed by BioStem Technologies Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-biostem-technologies-inc-6784106)
- 2026-11-10 21:15 UTC [SEC Schedule 13G] [SEC Form SCHEDULE 13G filed by BioStem Technologies Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-biostem-technologies-inc-6784096)
- 2026-11-05 12:59 UTC [SEC Schedule 13G] [SEC Form SCHEDULE 13G filed by BioStem Technologies Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-biostem-technologies-inc-6774832)
- 2026-11-03 21:30 UTC [SEC Form 4] [Chief Commercial Officer Hassett Barry converted options into 253 shares, increasing direct ownership by 5% to 5,256 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-commercial-officer-hassett-barry-converted-options-into-253-shares-6770084)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/BSEM
- Earnings history: https://www.quantisnow.com/earnings/BSEM
- Dividend history: https://www.quantisnow.com/dividends/BSEM
- Insider transactions: https://www.quantisnow.com/insiders/BSEM
- Options chain: https://www.quantisnow.com/options/BSEM
- SEC 8-K filings only: https://www.quantisnow.com/company/BSEM/8-k
- RSS and alerts for BSEM: https://www.quantisnow.com/docs/rss-feeds.md
